Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

8.280 UNCHANGED
Last Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
41 42 Next >
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Portfolio to Secure New European Patent
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Granted Two US Patents Protecting Exclusive Deuterated DMT Program
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program
From Cybin Inc.
Via Business Wire
News headline image
Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics ↗
Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement. 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
News headline image
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted ↗
Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts 
Via Benzinga
News headline image
Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business ↗
Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc. 
Via Benzinga
News headline image
Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement ↗
Short-acting psychedelics biotech Small Pharma Inc. 
Via Benzinga
News headline image
Small Pharma Obtains Final Order Approving Arrangement
From Cybin Inc.
Via Business Wire
News headline image
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More ↗
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution 
Via Benzinga
News headline image
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates ↗
Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc. 
Via Benzinga
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Reports on Voting Results from Annual Shareholder Meeting
Via Investor Brand Network
News headline image
Cybin Announces Results of Annual and Special Meeting of Shareholders
From Cybin Inc.
Via Business Wire
News headline image
Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More ↗
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares 
Via Benzinga
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Abstract Selected for Presentation at Sixth Annual Neuropsychiatric Drug Development Summit
Via Investor Brand Network
News headline image
Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
Via Investor Brand Network
News headline image
Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit
From Cybin Inc.
Via Business Wire
News headline image
Cybin Completes Dosing In Phase 2 Study Of CYB003 For Major Depressive Disorder Treatment ↗
Cybin Inc. (NYSE: CYBN), a clinical-stage biotech company developing novel psychedelic-based mental health treatments, has completed dosing of the final participant cohort in the 
Via Benzinga
News headline image
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares ↗
NY Mets owner billionaire Steve Cohen has bought as many as 119,092,680 ordinary shares of clinical-stage biopharmaceutical company Bionomics Limited (NASDAQ: BNOX) through his Point72 asset management... 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Wraps Up Phase 2 Study Dosing for Final Cohort
Via Investor Brand Network
News headline image
Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
News headline image
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More ↗
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Positive Top-Line Data Gathered from Small Pharma Study
Via Investor Brand Network
News headline image
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
From Cybin Inc.
Via Business Wire
News headline image
Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression ↗
Clinical-stage psychedelics biotech Cybin Inc. 
Via Benzinga
News headline image
Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results ↗
New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out. 
Via Benzinga
News headline image
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More ↗
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge 
Via Benzinga
Topics Economy
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.